The Cambridge drugmaker has laid out ambitious plans for its FDA-required confirmatory trial of its Alzheimer’s drug, Aduhelm. The plans include a diverse patient cohort, as well as new endpoints designed to rate patients’ levels of cognitive impairment.
Read More
